Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriGlytza-01 in Overweight and Obese Adults With Type 2 Diabetes
NCT07139405Phase 2Not yet recruiting
- Sponsor
- Myopharm
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Myopharm. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 16 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07139405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139405.